壽康(00575.HK):Senstend中國第三期隨機臨床顯示早洩治療對患者有良好耐受性
壽康集團(00575.HK)公布,其商業戰略合作夥伴江蘇萬邦醫藥在中國進行的Senstend治療早洩的第三期雙盲安慰劑對照研究已經完成。
該研究取得十分優秀的成果,已達到陰道內射精潛伏時間、早洩指數射精控制、早洩指數性滿足範疇以及早洩指數困擾的所有四個共同主要終點。與基線及安慰劑相比,Senstend在陰道內射精潛伏時間、射精控制及滿意度方面在臨床及數據上的表現顯著較好,並減少痛苦。與集團之前在歐洲及美國進行的研究一樣,Senstend得到了中國患者及伴侶的良好耐受,且並無報告新的副作用。
該研究共納入295名20歲或以上,被診斷為早洩的男性患者,其中197名患者被分配到SenstendTM組,98名患者被分配到安慰劑組;患者在中國11個地點接受了為期三個月的治療。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.